Podcast

Adding Tools to the Toolbox: New and Emerging Treatments for Psoriatic Arthritis

Launch Date
01/25/2021
Credit Amount
0.00 Expired
Credit Expires
02/25/2022

Faculty

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Weill Cornell Medicine
Attending Rheumatologist and Co-Director, Clinic for Inflammatory Arthritis, Hospital for Special Surgery, New York, NY
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Allan Gibofsky, MD, JD, MACR, FACP, FCLM, serves as Professor of Medicine in the Department of Healthcare Policy and Research at Weill Cornell Medicine. Dr Gibofsky is an attending physician and rheumatologist at the Hospital for Special Surgery, where he is Co- Director of the Clinic for Inflammatory Arthritis. He received his undergraduate degree from Brooklyn College of the City University of New York, his medical degree from Weill Medical College of Cornell University, and his law degree from Fordham University School of Law. He did his internship in pathology, followed by a residency in medicine at New York Hospital. He completed a fellowship in rheumatology/immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr Gibofsky has authored or co-authored numerous papers and textbook chapters, primarily on rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular, for his basic and clinical studies on rheumatic fever.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and is a recipient of its Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees and was Chair for Professional Education. Dr Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He served as President of The American College of Rheumatology and was recently named a Master. Dr Gibofsky is a Jonas Salk Scholar of the City University and an Alumnus of the Year of Brooklyn College. He is past President of the American College of Legal Medicine and is past Chair of the American Board of Legal Medicine. Dr Gibofsky is past Chair of the Arthritis Advisory Committee of the Food and Drug Administration and continues as a special consultant to that committee.

April W. Armstrong, MD, MPH
Associate Dean, Clinical Research Professor of Dermatology Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine University of Southern California Los Angeles, CA
April W. Armstrong, MD, MPH

Dr. April Armstrong is Associate Dean at Keck School of Medicine of the University of Southern California (USC). She also serves as Director of Clinical Research Support at the Southern California Clinical and Translational Science Institute (CTSI). Dr. Armstrong also serves as Vice Chair and Director of Psoriasis Program in the dermatology department at USC. Dr. Armstrong obtained her MD and completed dermatology residency at Harvard. She also obtained a MPH in Clinical Effectiveness from Harvard School of Public Health.

Dr. Armstrong is highly committed to clinical research and the care of patients with inflammatory skin diseases such as psoriasis and atopic dermatitis. Her research focuses on (1) investigating comorbidities related to psoriasis and atopic dermatitis, (2) identifying treatment patterns, treatment goals, and economic burden of inflammatory skin disease, and (3) increasing patient access using innovative, technology-enabled healthcare delivery methods. She has conducted over 100 clinical trials and published over 210 articles in scientific journals. She holds multiple leadership positions at professional societies, including the National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Psoriasis Council, and the American Academy of Dermatology. She is an associate Editor for JAMA Dermatology and has also served on the editorial boards of JAAD and Telemedicine and eHealth.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

The principles of psoriatic arthritis (PsA) treatment include reducing pain, improving quality of life, preventing structural damage and complications, engaging patients in shared decision-making, and identifying comorbidities that may impact treatment decisions. This requires management by a multidisciplinary team. Novel agents and treatment targets have demonstrated efficacy in PsA. Education is needed to ensure that the most up-to-date evidence informs treatment decision-making to optimize patient outcomes.

In this CMEOCast podcast, expert faculty will present key clinical efficacy and safety data for novel and emerging agents and discuss how best to apply this data to treatment decisions in patients with PsA.

Learning Objectives

At the end of this CME/CE activity, participants should be able to apply key clinical efficacy and safety data for novel and emerging agents to treatment decisions in patients with PsA.

The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize the key clinical efficacy and safety data for novel and emerging agents for PsA.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Rheumatologists, dermatologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Armstrong reports that she receives grants or research support from AbbVie Inc.; Boehringer Ingelheim/Parexel; Bristol-Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; Janssen-Ortho, Inc.; Janssen Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Leo Pharma Inc.; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharma, and UCB Pharma. She is on the speakers bureau for AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-059-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 

PD-045-022521-01

Adding Tools to the Toolbox: New and Emerging Treatments for Psoriatic Arthritis
Event Date: 01/25/2021